Clover Biopharmaceuticals, Ltd. (HKG:2197)
Hong Kong
· Delayed Price · Currency is HKD 2.970
+0.110 (3.85%)
Apr 29, 2026, 4:08 PM HKT
Clover Biopharmaceuticals Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2019 |
| Revenue | 3.51 | 38.42 | 39.26 | - | - | Upgrade
|
| Revenue Growth (YoY) | -90.88% | -2.13% | - | - | - | Upgrade
|
| Cost of Revenue | 0.2 | 711.36 | 1,712 | 475.64 | 66.27 | Upgrade
|
| Gross Profit | 3.31 | -672.94 | -1,673 | -475.64 | -66.27 | Upgrade
|
| Selling, General & Admin | 71.4 | 94.88 | 253.58 | 410.24 | 345.71 | Upgrade
|
| Research & Development | 182.34 | 183.39 | 649.89 | 1,465 | 1,826 | Upgrade
|
| Other Operating Expenses | 4.46 | 3.63 | 24.59 | 49.01 | 0.43 | Upgrade
|
| Operating Expenses | 258.2 | 281.9 | 928.05 | 1,925 | 2,172 | Upgrade
|
| Operating Income | -254.89 | -954.84 | -2,601 | -2,400 | -2,239 | Upgrade
|
| Interest Expense | -0.38 | -5.76 | -18.72 | -5.93 | -8.22 | Upgrade
|
| Interest & Investment Income | 6.33 | 23.69 | 16.12 | 8.51 | 10.89 | Upgrade
|
| Currency Exchange Gain (Loss) | 11.46 | -23.85 | -34.98 | -25.41 | 10.35 | Upgrade
|
| Other Non Operating Income (Expenses) | 36.13 | 16.58 | 12.43 | 14.51 | 16.11 | Upgrade
|
| EBT Excluding Unusual Items | -201.35 | -944.19 | -2,626 | -2,409 | -2,210 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | -13.84 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.17 | 0.4 | - | 0.23 | 0.91 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.01 | 2 | -4.74 | -8.43 | - | Upgrade
|
| Asset Writedown | -0.02 | -14.01 | -10.31 | - | - | Upgrade
|
| Other Unusual Items | -3.9 | 52.37 | 2,503 | -21.32 | -3,808 | Upgrade
|
| Pretax Income | -205.09 | -903.43 | -138.54 | -2,452 | -6,016 | Upgrade
|
| Net Income | -205.09 | -903.43 | -138.54 | -2,452 | -6,016 | Upgrade
|
| Net Income to Common | -205.09 | -903.43 | -138.54 | -2,452 | -6,016 | Upgrade
|
| Shares Outstanding (Basic) | 1,260 | 1,254 | 1,244 | 1,102 | 1,158 | Upgrade
|
| Shares Outstanding (Diluted) | 1,260 | 1,254 | 1,244 | 1,102 | 1,158 | Upgrade
|
| Shares Change (YoY) | 0.53% | 0.82% | 12.83% | -4.84% | 52.85% | Upgrade
|
| EPS (Basic) | -0.16 | -0.72 | -0.11 | -2.22 | -5.19 | Upgrade
|
| EPS (Diluted) | -0.16 | -0.72 | -0.11 | -2.22 | -5.19 | Upgrade
|
| Free Cash Flow | - | -289.62 | -734.83 | -1,768 | -977 | Upgrade
|
| Free Cash Flow Per Share | - | -0.23 | -0.59 | -1.60 | -0.84 | Upgrade
|
| Gross Margin | 94.29% | - | - | - | - | Upgrade
|
| Operating Margin | -7272.18% | -2485.33% | -6626.46% | - | - | Upgrade
|
| Profit Margin | -5851.41% | -2351.51% | -352.92% | - | - | Upgrade
|
| Free Cash Flow Margin | - | -753.84% | -1871.94% | - | - | Upgrade
|
| EBITDA | -226.48 | -926.43 | -2,563 | -2,371 | -2,226 | Upgrade
|
| D&A For EBITDA | 28.41 | 28.41 | 38.3 | 28.98 | 12.29 | Upgrade
|
| EBIT | -254.89 | -954.84 | -2,601 | -2,400 | -2,239 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.